Carpenter Kristen M, Conroy Katherine, Black Lora L, Salani Ritu, Lustberg Maryam
The Ohio State University Wexner Medical Center, Columbus, OH, USA.
University of Washington, Seattle, WA, USA.
Support Care Cancer. 2025 Aug 28;33(9):818. doi: 10.1007/s00520-025-09858-z.
Sexual inactivity has been shown to be a predictor of future sexual problems and related distress in female cancer survivors; however, very little is known about the sexual lives of women in active treatment. The aims of present study are to estimate rates of sexual activity during adjuvant chemotherapy and their relationship to sexual outcomes 12 months after therapy initiation.
Self-report questionnaires were completed by gynecologic and breast cancer patients (n = 58) prior to their first chemotherapy infusion, at three timepoints during treatment, and at follow-up 1 year later. Questionnaires assessed sexual activity, sexual desire, sexual arousal, sexual satisfaction, depressive symptoms, and treatment toxicities.
Engagement in sexual activity during chemotherapy was significantly associated with reports of experiencing sexual desire (B = 1.94, p = .03), arousal (B = 3.31, p = .01), and higher satisfaction ratings (β = .33, p = .02) 12 months after the initiation of chemotherapy.
The results indicate that remaining sexually active during treatment is associated with better sexual function and higher sexual satisfaction in the year following chemotherapy initiation.
性活动减少已被证明是女性癌症幸存者未来性问题及相关困扰的一个预测指标；然而，对于正在接受积极治疗的女性的性生活情况却知之甚少。本研究的目的是评估辅助化疗期间的性活动发生率及其与治疗开始后12个月时性结局的关系。
妇科和乳腺癌患者（n = 58）在首次化疗输注前、治疗期间的三个时间点以及1年后的随访时完成自我报告问卷。问卷评估了性活动、性欲、性唤起、性满意度、抑郁症状和治疗毒性。
化疗期间的性活动与化疗开始后12个月时出现性欲（B = 1.94，p = 0.03）、性唤起（B = 3.31，p = 0.01）以及更高满意度评分（β = 0.33，p = 0.02）的报告显著相关。
结果表明，治疗期间保持性活动与化疗开始后一年内更好的性功能和更高的性满意度相关。
